Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S)

被引：0
|
作者：
Jonasch, Eric
Hasanov, Elshad
Motzer, Robert J.
Hariharan, Subramanian
Choueiri, Toni K.
Huang, Bo
Haanen, John B. A. G.
Albiges, Laurence
Venugopal, Balaji
Schmidinger, Manuela
Larkin, James M. G.
Grimm, Marc-Oliver
Negrier, Sylvie
Wang, Jing
Mariani, Mariangela
Chudnovsky, Aleksander
di Pietro, Alessandra
Rini, Brian I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Pfizer Inc, New York, NY USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Boston, MA USA
[6] Pfizer Inc, Groton, CT 06340 USA
[7] Netherlands Canc Inst, Amsterdam, Netherlands
[8] Inst Gustave Roussy, Villejuif, France
[9] Univ Glasgow, Glasgow, Lanark, Scotland
[10] Med Univ Vienna, Vienna, Austria
[11] Royal Marsden NHS Fdn Trust, London, England
[12] Jena Univ Hosp, Jena, Germany
[13] Univ Lyon, Ctr Leon Berard, Lyon, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Pfizer SRL, Milan, Italy
[16] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK Perspective
    De Mello, Ramon Andrade
    Ayoub, Emili
    Castelo-Branco, Pedro
    De Almeida Zia, Victor Andre
    Savio, Andre
    Pozza, Daniel Humberto
    Tadokoro, Hakaru
    Teich, Nelson
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Choueiri, Toni K.
    Rini, Brian I.
    Cosgriff, Thomas
    Miyake, Hideaki
    Vogelzang, Nicholas J.
    Kannourakis, George
    Mariani, Mariangela
    Chiruzzi, Chiara
    Albiges, Laurence
    Haanen, John B.
    Larkin, James
    Atkins, Michael B.
    Schmidinger, Manuela
    Magazzu, Domenico
    Di Pietro, Alessandra
    Motzer, Robert J.
    BJU INTERNATIONAL, 2016, 118 : 29 - 30
  • [43] Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial (vol 6, 100101, 2021)
    Choueiri, T. K.
    Larkin, J.
    Pal, S.
    Motzer, R. J.
    Rini, B. I.
    Venugopal, B.
    Alekseev, B.
    Miyake, H.
    Gravis, G.
    Bilen, M. A.
    Hariharan, S.
    Chudnovsky, A.
    Ching, K. A.
    Mu, X. J.
    Mariani, M.
    Robbins, P. B.
    Huang, B.
    Di Pietro, A.
    Albiges, L.
    ESMO OPEN, 2021, 6 (04)
  • [44] Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report
    Uekawa, Ayano
    Kurahashi, Ryoma
    Motoshima, Takanobu
    Murakami, Yoji
    Yatsuda, Junji
    Kamba, Tomomi
    UROLOGY CASE REPORTS, 2022, 45
  • [45] Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.
    Bello, Carlo
    Brar, Satjit
    Masters, Joanna C.
    Khandelwal, Akash
    Novakovic, Ana M.
    Ruiz-Garcia, Ana
    Hibma, Jennifer
    CANCER RESEARCH, 2021, 81 (13)
  • [46] UK real-world observational study of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results.
    Nathan, Paul D.
    Charnley, Natalie
    Frazer, Ricky
    McGrane, John
    Muazzam, Iqtedar A.
    Rudman, Sarah
    Sharma, Anand
    Stevenson, Robert
    Hickey, Joseph David
    Tahim, Arpan
    Ritchie, Aimi Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [47] Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
    Larkin, James
    Oya, Mototsugu
    Martignoni, Marcella
    Thistlethwaite, Fiona
    Nathan, Paul
    Ornstein, Moshe C.
    Powles, Thomas
    Beckermann, Kathryn E.
    Balar, Arjun, V
    McDermott, David
    Gupta, Sumati
    Philips, George K.
    Gordon, Michael S.
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Wang, Jing
    Michelon, Elisabete
    di Pietro, Alessandra
    Choueiri, Toni K.
    ONCOLOGIST, 2022, : 333 - 340
  • [48] A UK real-world observational study of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.
    Nathan, Paul D.
    Charnley, Natalie
    Frazer, Ricky
    McGrane, John
    Muazzam, Iqtedar
    Pillai, Manon
    Rudman, Sarah
    Stevenson, Robert
    Venugopal, Balaji
    Hickey, Joseph David
    Ritchie, Aimi Rose
    Liu, Kin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 386 - 386
  • [49] Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
    Tsimafeyeu, Ilya
    Chubenko, Vyacheslav
    Baklanova, Olga
    Kalpinskiy, Alexey
    Safina, Sufia
    Lebedinets, Andrei
    Petkau, Vladislav
    Parsadanova, Elvira
    Turganova, Maria
    Shkurat, Aleksei
    Tovbik, Natalia
    Tkacheva, Elena
    Anzhiganova, Yulia
    Novikova, Olga
    Bragina, Varvara
    Zukov, Ruslan
    Orlova, Rashida
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [50] Cost-Effectivenessof Pembrolizumab plus Axitinib Versus Sunitinib asFirst-LineTherapy in Advanced Renal Cell Carcinoma in the US
    Ding, Dong
    Hu, Huabin
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Shen, Liangfang
    Huang, Jin
    ONCOLOGIST, 2021, 26 (02): : E290 - E297
12345